Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty - Wesley Research Institute
Wesley Research Institute
Donate
Now

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement.

Research Objectives

Status

Current

Recruitment

Open

Estimated completion

December 2023

Patient Group

Patients undergoing total knee replacement surgery (arthroplasty)

Total Participants

80

Study location

Wesley Research Institute, Griffith University

Study type

Investigator Initiated
find out if you’re eligible

Lead investigator

  • A/Prof Susan Clark

Experienced investigator

  • Prof Robert Ware

Clinical trial coordinator

  • Emma Brownrigg

Technical title

A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty (TXA002)

About this research project

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement. The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of you needing a blood transfusion and may decrease pain, swelling and recovery time following the operation. Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about the best dosing of the drug to achieve optimal patient outcomes. This study will assess whether different treatment durations will lead to better results for patients.

Latest News

Jillian’s Story

This was my first experience at being involved in any sort of research. If I get the opportunity again, I would definitely put my hand up after the wonderful experience I had with your team. Thank you so much to Emma and all your team for making me feel so welcome.    Jillian Meet Jillian, retired […]

Breaking Ground in Paediatric Rare Disease Research

Wesley Research Institute is home to a groundbreaking trial using triheptanoin, a dietary fat, to treat Ataxia-Telangiectasia (A-T), a rare degenerative neurological disorder. This trial has shown promising results, with observed improvements in neurology scales and cellular biomarkers indicating the treatment’s effectiveness.

World-First ‘Back to the Future’ Research Set To Boost Pandemic Protection  

A world-first research project by two Queensland professors is set to offer a blueprint for developing more effective vaccines and therapies specifically tailored to safeguard the health of children and young adults in times of global health crises.  Spearheaded by Professor John Fraser, Dr Arutha Kulasinghe and Associate Professor Kirsty Short, this pioneering study, funded […]
1 2 3 12
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram